Nrx Pharmaceuticals, INC. 8-K Filing

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock , par value $0.001 pershare NRXP The Nasdaq Stock Marke

Filing Documents

• nrxp20251125_8k.htm (8-K) — 34KB
• ex_893504.htm (EX-16.1) — 5KB
• logo0.jpg (GRAPHIC) — 30KB
• sig0.jpg (GRAPHIC) — 12KB
• 0001437749-25-036452.txt ( ) — 242KB
• nrxp-20251120.xsd (EX-101.SCH) — 4KB
• nrxp-20251120_def.xml (EX-101.DEF) — 13KB
• nrxp-20251120_lab.xml (EX-101.LAB) — 17KB
• nrxp-20251120_pre.xml (EX-101.PRE) — 13KB
• nrxp20251125_8k_htm.xml (XML) — 5KB

01 Changes in Registrant ' s Certifying Accountant

Item 4.01 Changes in Registrant ' s Certifying Accountant. Engagement of New Independent Registered Public Accounting Firm and Dismissal of Independent Registered Public Accounting Firm On November 20, 2025, the audit committee of the board of directors (the "Audit Committee") of NRx Pharmaceuticals, Inc. (the "Corporation") approved the engagement of Weinberg & Company P.A. ("Weinberg") as the Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg had been previously engaged to audit the financial statements of Dura Medical LLC, which had been acquired by Hope Therapeutics, Inc. ("HOPE"), a subsidiary of the Corporation. During the Corporation's two most recent fiscal years and the subsequent interim period through September 30, 2025, neither the Corporation, nor anyone on its behalf, consulted Weinberg regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Corporation's financial statements, and neither a written report nor oral advice was provided to the Corporation that Weinberg concluded was an important factor considered by the Corporation in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event of the type described in Item 304(a)(1)(v) of Regulation S-K. For the reason stated above, on or around November 24, 2025 the Audit Committee of the Corporation dismissed Salberg & Company P.A. ("Salberg") as the Corporation's independent registered public accounting firm. Salberg's audit reports on the Corporation's consolidated financial statements fo

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 16.1* Letter from Salberg & Company P.A. to the SEC dated November 25, 2025. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NRx Pharmaceuticals, Inc. Date: November 26, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Its: Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR